⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight
globenewswire.com
MDT
LIVN
BSX
THC
AMGN
AZN
PFE
JNJ
MRNA
BMY
GILD
REGN
TEVA
CL
PG
KO
PEP
DIS
NVDA
GOOG
AMZN
MSFT
AAPL
TSLA
META
CRM
ADBE
NFLX
INTC
AMD
QCOM
CMCSA
T
VZ
IBM
ORCL
CSCO
ACN
HON
GE
BA
CAT
XOM
CVX
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
HD
MCD
SBUX
COST
WMT
TGT
LOW
CVS
UNH
CI
ETSY
ROKU
PYPL
MELI
EBAY
BABA
JD
PDD
NTES
BIDU
TM
SONY
SAP
AIR
ASML
BNTX
NVO
BP
FCX
BHP
RIO
VALE
NKE
LULU
UA
CROX
NOC
GD
LMT
RTX
AVGO
AMAT
LRCX
MU
NXPI
MRVL
SNPS
CDNS
VRTX
BIIB
LLY
ABBV
MRK
CHTR
CMG
SIRI
GEHC
GSK
SNY
MREO
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
businesswire.com
GILD
Form 8-K
sec.gov
TENX
LNSR
BCRX
MRK
GILD
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
businesswire.com
MRK
GILD
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD
Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda
globenewswire.com
MRK
BMY
GILD
TAK
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL USA - English USA - English
prnewswire.com
MRK
GSK
GILD
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL USA - English USA - English
prnewswire.com
MRK
GSK
GILD
Form 8-K
sec.gov
RCUS
GILD
New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
prnewswire.com
GILD